10 Most Undervalued Long Term Stocks to Buy Now

6. Bristol-Myers Squibb Company (NYSE:BMY)

Forward P/E as on February 28: ~8.8x

10-Year Sales Growth: ~11.7%

Number of Hedge Fund Holders: 88

Bristol-Myers Squibb Company (NYSE:BMY) is engaged in discovering, developing, licensing, manufacturing, marketing, distributing, and selling biopharmaceutical products. The company made good progress in 2024, with a healthy Q4 2024 topline growth fueled by critical products and important pipeline advancements. Bristol-Myers Squibb Company (NYSE:BMY) achieved the landmark US approval of Cobenfy last year for the treatment of schizophrenia in adults, and it projects this medicine to have a significant impact on patients and the company as a new growth enabler.

In Q4 2024, the company saw revenues of $12.3 billion, reflecting a rise of 8%, or 9% when adjusted for foreign exchange impacts, primarily due to Growth Portfolio and increased demand for Eliquis, partially mitigated by the impact of generics on Sprycel, Revlimid, Abraxane and Pomalyst. In a positive development, Bristol-Myers Squibb Company (NYSE:BMY) announced that the US Food and Drug Administration (FDA) has accepted the supplemental biologics license application for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a potential first-line treatment option for adult and pediatric patients (12 years and older) with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (mCRC). Bristol-Myers Squibb Company (NYSE:BMY) possesses significant opportunities for growth and expansion. Its focus on cell therapies and targeted protein degraders in hematology and oncology can offer avenues for long-term success.